Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Golden Heaven Group Holdings Ltd. (GDHG) : 0.3298-0.0402 (-10.8649%)
https://twitter.com/GoldenHeavenLTD/status/1775989104993308925/photo/1
If the trailing P/E returned to historical form, the stock would trade at 2.42.
Golden Heaven Group Holdings Ltd. (GDHG) : 0.3298-0.0402 (-10.8649%)
https://ir.jsyoule.com/
collaborations, increased visitors, 6 M Share repurchase program, expand into Indonesia market,…
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities.
Time for a very strong rebound!!!
Apr 05, 2024 0.3298
Apr 04, 2024 0.4330
Apr 03, 2024 0.4550
Apr 02, 2024 0.4650
Apr 01, 2024 0.4850
Mar 28, 2024 0.4790
Mar 27, 2024 0.4780
Mar 26, 2024 0.5360
Dec 07, 2023 20.8800 22.3000 2.2000 2.3200 2.3200 8,769,800
Dec 06, 2023 20.9900 21.7400 19.5880 21.0800 21.0800 335,600
Dec 05, 2023 19.8100 20.8100 19.1700 20.5800 20.5800 304,900
Dec 04, 2023 19.5300 20.8000 19.0000 20.1400 20.1400 290,700
Dec 01, 2023 22.0000 22.0000 19.7500 20.5500 20.5500 336,200
Nov 30, 2023 23.0000 23.5300 21.4100 21.5800 21.5800 360,000
Nov 29, 2023 23.1400 23.5000 21.4400 23.0600 23.0600 270,800
Nov 28, 2023 23.4100 24.5500 22.0000 23.1000 23.1000 391,900
Nov 27, 2023 22.5200 24.8300 21.2000 24.3100 24.3100 475,500
Nov 24, 2023 24.3000 24.3000 19.7500 23.4900 23.4900 355,500
Nov 22, 2023 22.0000 22.7100 21.6300 22.6000 22.6000 330,600
Nov 21, 2023 22.5000 24.3000 21.0000 21.5000 21.5000 349,800
Nov 20, 2023 21.8200 23.8100 20.6400 23.4500 23.4500 392,600
Nov 17, 2023 18.1300 21.4300 16.6600 20.3900 20.3900 404,300
Nov 16, 2023 20.3500 20.4710 17.8000 18.4300 18.4300 357,300
Nov 15, 2023 19.5100 22.9000 19.1100 19.7800 19.7800 323,100
Nov 14, 2023 14.6200 20.0000 14.6200 19.6400 19.6400 456,300
Nov 13, 2023 23.0000 24.9900 11.0050 17.1200 17.1200 1,006,300
Nov 10, 2023 21.9300 24.6300 20.7450 23.7500 23.7500 304,100
Nov 09, 2023 19.9900 22.0000 18.5000 21.3500 21.3500 371,600
Golden Heaven Group Holdings Ltd. (GDHG) : 0.3298-0.0402 (-10.8649%)
https://ir.jsyoule.com/
collaborations, increased visitors, 6 M Share repurchase program, expand into Indonesia market,…
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities.
Time for a very strong rebound!!!
Apr 05, 2024 0.3298
Apr 04, 2024 0.4330
Apr 03, 2024 0.4550
Apr 02, 2024 0.4650
Apr 01, 2024 0.4850
Mar 28, 2024 0.4790
Mar 27, 2024 0.4780
Mar 26, 2024 0.5360
Dec 07, 2023 20.8800 22.3000 2.2000 2.3200 2.3200 8,769,800
Dec 06, 2023 20.9900 21.7400 19.5880 21.0800 21.0800 335,600
Dec 05, 2023 19.8100 20.8100 19.1700 20.5800 20.5800 304,900
Dec 04, 2023 19.5300 20.8000 19.0000 20.1400 20.1400 290,700
Dec 01, 2023 22.0000 22.0000 19.7500 20.5500 20.5500 336,200
Nov 30, 2023 23.0000 23.5300 21.4100 21.5800 21.5800 360,000
Nov 29, 2023 23.1400 23.5000 21.4400 23.0600 23.0600 270,800
Nov 28, 2023 23.4100 24.5500 22.0000 23.1000 23.1000 391,900
Nov 27, 2023 22.5200 24.8300 21.2000 24.3100 24.3100 475,500
Nov 24, 2023 24.3000 24.3000 19.7500 23.4900 23.4900 355,500
Nov 22, 2023 22.0000 22.7100 21.6300 22.6000 22.6000 330,600
Nov 21, 2023 22.5000 24.3000 21.0000 21.5000 21.5000 349,800
Nov 20, 2023 21.8200 23.8100 20.6400 23.4500 23.4500 392,600
Nov 17, 2023 18.1300 21.4300 16.6600 20.3900 20.3900 404,300
Nov 16, 2023 20.3500 20.4710 17.8000 18.4300 18.4300 357,300
Nov 15, 2023 19.5100 22.9000 19.1100 19.7800 19.7800 323,100
Nov 14, 2023 14.6200 20.0000 14.6200 19.6400 19.6400 456,300
Nov 13, 2023 23.0000 24.9900 11.0050 17.1200 17.1200 1,006,300
Nov 10, 2023 21.9300 24.6300 20.7450 23.7500 23.7500 304,100
Nov 09, 2023 19.9900 22.0000 18.5000 21.3500 21.3500 371,600
Astrotech Corporation (ASTC) : 8.86+0.26 (+3.04%)
52 Week Range 7.00 - 15.11
Total Cash (mrq) 37.28M
Total Cash Per Share (mrq) 22.86
Total Debt (mrq) 461k
Book Value Per Share (mrq) 24.69
Shares Outstanding 5 1.7M
Implied Shares Outstanding 6 1.7M
Float 1.2M
The TRACER 1000™ is a mass spectrometry-based trace analyzer; its detection library now includes narcotics such as fentanyl, heroin, and cocaine.
AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ: ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (NTD).
The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds. Currently, the Company’s Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world. The NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo, and infrastructure security, correctional facilities, military, and law enforcement.
The Astrotech Mass Spectrometer Technology™ (AMS Technology) drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry as a trace detection security solution. As stated by Dr. Laura Parker, R&D Program Manager from the U.S. Department of Homeland Security, mass spectrometers are the “gold standard” of chemical detection1. The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security.
Using the same successful AMS Technology, the TRACER 1000 NTD maintains the accuracy of much larger mass-spectrometers even though it is only the size of a desktop printer. While mass spectrometry has historically been too costly, bulky, and cumbersome to be used outside of the laboratory, the simple-to-use interface and auto-calibration process of the TRACER 1000 NTD make it easy to use for rank-and-file checkpoint or other security personnel, at a fraction of the cost of traditional mass-spectrometers.
“Over the last five years our ETD instruments have proven their durability, reliability, and their specificity with a false alarm rate of less than 2% in actual airport and cargo environments. We are very excited about introducing our narcotics detection library that includes twelve illegal drugs including fentanyl, heroin, and cocaine. And we look forward to providing the same level of quality instrumentation to the narcotic trace detector customer,” said Thomas B. Pickens, III, Astrotech’s Chairman, Chief Executive Officer, and Chief Technology Officer.
About Astrotech
Astrotech is an innovative science and technology company that invents, acquires, and commercializes technological innovations while building scalable companies to maximize shareholder value. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.
Astrotech Corporation (ASTC) : 8.86+0.26 (+3.04%)
52 Week Range 7.00 - 15.11
Total Cash (mrq) 37.28M
Total Cash Per Share (mrq) 22.86
Total Debt (mrq) 461k
Book Value Per Share (mrq) 24.69
Shares Outstanding 5 1.7M
Implied Shares Outstanding 6 1.7M
Float 1.2M
The TRACER 1000™ is a mass spectrometry-based trace analyzer; its detection library now includes narcotics such as fentanyl, heroin, and cocaine.
AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ: ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (NTD).
The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds. Currently, the Company’s Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world. The NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo, and infrastructure security, correctional facilities, military, and law enforcement.
The Astrotech Mass Spectrometer Technology™ (AMS Technology) drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry as a trace detection security solution. As stated by Dr. Laura Parker, R&D Program Manager from the U.S. Department of Homeland Security, mass spectrometers are the “gold standard” of chemical detection1. The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security.
Using the same successful AMS Technology, the TRACER 1000 NTD maintains the accuracy of much larger mass-spectrometers even though it is only the size of a desktop printer. While mass spectrometry has historically been too costly, bulky, and cumbersome to be used outside of the laboratory, the simple-to-use interface and auto-calibration process of the TRACER 1000 NTD make it easy to use for rank-and-file checkpoint or other security personnel, at a fraction of the cost of traditional mass-spectrometers.
“Over the last five years our ETD instruments have proven their durability, reliability, and their specificity with a false alarm rate of less than 2% in actual airport and cargo environments. We are very excited about introducing our narcotics detection library that includes twelve illegal drugs including fentanyl, heroin, and cocaine. And we look forward to providing the same level of quality instrumentation to the narcotic trace detector customer,” said Thomas B. Pickens, III, Astrotech’s Chairman, Chief Executive Officer, and Chief Technology Officer.
About Astrotech
Astrotech is an innovative science and technology company that invents, acquires, and commercializes technological innovations while building scalable companies to maximize shareholder value. 1st Detect develops, manufactures, and sells trace detectors for use in the security and detection market. Astrotech is headquartered in Austin, Texas. For information, please visit www.astrotechcorp.com.
BIOSENIC BE0974280126 : 0.026 + 17.2%
https://finance.yahoo.com/news/biosenic-presents-successful-preclinical-data-060000014.html
0,025 4.947 2
0,026 35.000 2
0,027 5.000 1
0,0272 78.853 1
0,028 5.000 1
0,0284 70.000 2
0,029 5.000 1
0,0294 25.000 1
0,0296 36.500 1
0,0298 210.000 1
Time for a strong rebound:
Mar 20, 2024 0.0236 0.0260 0.0216 0.0216 0.0216 2,119,991
Mar 17, 2024 0.0238 0.0246 0.0120 0.0222 0.0222 3,236,969
Mar 10, 2024 0.0300 0.0300 0.0228 0.0230 0.0230 7,678,158
Mar 03, 2024 0.0326 0.0326 0.0294 0.0300 0.0300 1,924,824
Feb 25, 2024 0.0280 0.0342 0.0274 0.0302 0.0302 2,706,472
Feb 18, 2024 0.0342 0.0342 0.0268 0.0274 0.0274 6,142,808
Feb 11, 2024 0.0350 0.0382 0.0318 0.0340 0.0340 4,354,856
Feb 04, 2024 0.0428 0.0460 0.0330 0.0344 0.0344 5,974,991
Jan 28, 2024 0.0412 0.0480 0.0360 0.0410 0.0410 10,327,022
Jan 21, 2024 0.0480 0.0480 0.0380 0.0400 0.0400 9,428,608
Jan 14, 2024 0.0550 0.0568 0.0420 0.0450 0.0450 5,988,620
Jan 07, 2024 0.0640 0.0654 0.0514 0.0520 0.0520 2,758,977
Dec 31, 2023 0.0612 0.0700 0.0600 0.0640 0.0640 3,754,047
Dec 24, 2023 0.0518 0.0800 0.0512 0.0612 0.0612 8,333,592
BIOSENIC BE0974280126 : 0.026 + 17.2%
https://finance.yahoo.com/news/biosenic-presents-successful-preclinical-data-060000014.html
0,025 4.947 2
0,026 35.000 2
0,027 5.000 1
0,0272 78.853 1
0,028 5.000 1
0,0284 70.000 2
0,029 5.000 1
0,0294 25.000 1
0,0296 36.500 1
0,0298 210.000 1
Time for a strong rebound:
Mar 20, 2024 0.0236 0.0260 0.0216 0.0216 0.0216 2,119,991
Mar 17, 2024 0.0238 0.0246 0.0120 0.0222 0.0222 3,236,969
Mar 10, 2024 0.0300 0.0300 0.0228 0.0230 0.0230 7,678,158
Mar 03, 2024 0.0326 0.0326 0.0294 0.0300 0.0300 1,924,824
Feb 25, 2024 0.0280 0.0342 0.0274 0.0302 0.0302 2,706,472
Feb 18, 2024 0.0342 0.0342 0.0268 0.0274 0.0274 6,142,808
Feb 11, 2024 0.0350 0.0382 0.0318 0.0340 0.0340 4,354,856
Feb 04, 2024 0.0428 0.0460 0.0330 0.0344 0.0344 5,974,991
Jan 28, 2024 0.0412 0.0480 0.0360 0.0410 0.0410 10,327,022
Jan 21, 2024 0.0480 0.0480 0.0380 0.0400 0.0400 9,428,608
Jan 14, 2024 0.0550 0.0568 0.0420 0.0450 0.0450 5,988,620
Jan 07, 2024 0.0640 0.0654 0.0514 0.0520 0.0520 2,758,977
Dec 31, 2023 0.0612 0.0700 0.0600 0.0640 0.0640 3,754,047
Dec 24, 2023 0.0518 0.0800 0.0512 0.0612 0.0612 8,333,592
GDHG maintained robust financials in fiscal year 2023, with a total revenue of $31.8 million and a net income of $6.5 million. As GDHG is profitable, Our Price-To-Earnings Ratio of 3.5x is a good value. #profits @Nasdaq $DIS $SEAS $SIX $FUN $CMCSA $GDHG #investors #amusementparks pic.twitter.com/SFn5NqHkXo
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) March 15, 2024
GDHG maintained robust financials in fiscal year 2023, with a total revenue of $31.8 million and a net income of $6.5 million. As GDHG is profitable, Our Price-To-Earnings Ratio of 3.5x is a good value. #profits @Nasdaq $DIS $SEAS $SIX $FUN $CMCSA $GDHG #investors #amusementparks pic.twitter.com/SFn5NqHkXo
— Golden Heaven Group Holdings Ltd. (@GoldenHeavenLTD) March 15, 2024
MULLEN AUTOMOTIVE (MULN) : 5.22
All time low
As of January 9, 2024, there were issued and outstanding 5,884,693 shares of common stock.
Jan 10 = $14.40 share = mktcap: 85 million
today
Shares Outstanding 5 6.55M
Float 6.33M
Total Cash (mrq) 81.51M
Total Cash Per Share (mrq) 12.44
Total Debt (mrq) 20.52M
Book Value Per Share (mrq) 35.78
Shares Short (Feb 29, 2024) 4 1.29M
Short % of Float (Feb 29, 2024) 4 23.08%
= mktcap: less than 35 million of 50 million less than 2 months ago.
Mullen Automotive, Inc., an electric vehicle company, manufactures, sells, and distributes electric vehicles. Its products include passenger electric vehicles and commercial vehicles; and provides solid-state polymer battery technology. The company is headquartered in Brea, California.
https://www.mullenusa.com/
MULLEN AUTOMOTIVE (MULN) : 5.22
All time low
As of January 9, 2024, there were issued and outstanding 5,884,693 shares of common stock.
Jan 10 = $14.40 share = mktcap: 85 million
today
Shares Outstanding 5 6.55M
Float 6.33M
Total Cash (mrq) 81.51M
Total Cash Per Share (mrq) 12.44
Total Debt (mrq) 20.52M
Book Value Per Share (mrq) 35.78
Shares Short (Feb 29, 2024) 4 1.29M
Short % of Float (Feb 29, 2024) 4 23.08%
= mktcap: less than 35 million of 50 million less than 2 months ago.
Mullen Automotive, Inc., an electric vehicle company, manufactures, sells, and distributes electric vehicles. Its products include passenger electric vehicles and commercial vehicles; and provides solid-state polymer battery technology. The company is headquartered in Brea, California.
https://www.mullenusa.com/
WW: 1.87
52w: 1.56 – 13.31
Time for a strong recovery:
WeightWatchers CEO Sima Sistani sent an internal memo to employees reassuring them that the company is financially sound and saying its new GLP-1 weight-loss drug clinicals business is growing faster than it said just two week ago when it released earnings and guidance.
WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster than expected.
The memo, shared with CNBC, comes after heavy selling in WW shares
In the memo, Sistani told employees she wanted “to take a moment to address some of the breathless media coverage.”
Concerns about the company’s significant debt load have made new headlines in recent weeks, however, the issue is not a new one and much of the debt is not due for years.
“These headlines are often just speculation,” Sistani wrote to employees. “We have strong liquidity and are not in a cash crunch. We have very attractive, long-term debt agreements, with no maturities due until 2028 and 2029.”
Guggenheim Partners analysts wrote in a note on Thursday that they are “unconcerned” about WW’s ability to service its debt, which includes roughly $945 million outstanding on a non-amortizing term loan that matures in April of 2028, and $500 million of notes due in April of 2029.
The company ended 2023 with approximately $109 million in cash, according to Guggenheim.
“Despite the high leverage, we believe WW will have no problem covering interest payments on the debt, and will ultimately be in a much better position to recapitalize the company in 2-3 years after the Clinical business scales. Moreover, we think any worries about a recapitalization or default this year are overblown,” the Guggenheim analysts wrote.
Guggenheim maintains a buy rating on the shares and $12 price target. WW shares closed at $1.87 on Thursday.
Last year, WW acquired Sequence, since rebranded as WeightWatchers Clinic, as a way to confront the threat of the GLP-1 drugs to its legacy business by having the ability to connect patients with clinicians who can prescribe the drugs and combine the drugs with a broader weight-loss program. The FDA mandates the drugs be used in conjunction with broader weight-loss diet and exercise methods.
Sistani said in the note to employees that since it reported on Feb. 28 and provided guidance for the year, its GLP-1 related clinicals business has grown quickly. “In fact, we are on track to beat our Q1 guidance for Clinic subscribers,” she wrote.
While any faster growth for the clinicals business is a plus, several analysts who cover the stock have told CNBC that the core weight-loss management business has to grow for investors to turn bullish on the stock, given the size of the legacy business relative to the new clinicals effort.
WW: 1.87
52w: 1.56 – 13.31
Time for a strong recovery:
WeightWatchers CEO Sima Sistani sent an internal memo to employees reassuring them that the company is financially sound and saying its new GLP-1 weight-loss drug clinicals business is growing faster than it said just two week ago when it released earnings and guidance.
WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial position of the company is solid and its new clinical business related to the threat of GLP-1 weight loss drugs is growing faster than expected.
The memo, shared with CNBC, comes after heavy selling in WW shares
In the memo, Sistani told employees she wanted “to take a moment to address some of the breathless media coverage.”
Concerns about the company’s significant debt load have made new headlines in recent weeks, however, the issue is not a new one and much of the debt is not due for years.
“These headlines are often just speculation,” Sistani wrote to employees. “We have strong liquidity and are not in a cash crunch. We have very attractive, long-term debt agreements, with no maturities due until 2028 and 2029.”
Guggenheim Partners analysts wrote in a note on Thursday that they are “unconcerned” about WW’s ability to service its debt, which includes roughly $945 million outstanding on a non-amortizing term loan that matures in April of 2028, and $500 million of notes due in April of 2029.
The company ended 2023 with approximately $109 million in cash, according to Guggenheim.
“Despite the high leverage, we believe WW will have no problem covering interest payments on the debt, and will ultimately be in a much better position to recapitalize the company in 2-3 years after the Clinical business scales. Moreover, we think any worries about a recapitalization or default this year are overblown,” the Guggenheim analysts wrote.
Guggenheim maintains a buy rating on the shares and $12 price target. WW shares closed at $1.87 on Thursday.
Last year, WW acquired Sequence, since rebranded as WeightWatchers Clinic, as a way to confront the threat of the GLP-1 drugs to its legacy business by having the ability to connect patients with clinicians who can prescribe the drugs and combine the drugs with a broader weight-loss program. The FDA mandates the drugs be used in conjunction with broader weight-loss diet and exercise methods.
Sistani said in the note to employees that since it reported on Feb. 28 and provided guidance for the year, its GLP-1 related clinicals business has grown quickly. “In fact, we are on track to beat our Q1 guidance for Clinic subscribers,” she wrote.
While any faster growth for the clinicals business is a plus, several analysts who cover the stock have told CNBC that the core weight-loss management business has to grow for investors to turn bullish on the stock, given the size of the legacy business relative to the new clinicals effort.
Nu Ride Inc (NRDE) : 2.3100+0.6000 (+35.09%)
On March 14, 2024, Nu Ride Inc. (NuRide), formerly known as Lordstown Motors Corp., emerged from bankruptcy as a public reporting company. The company emerged from bankruptcy with approximately $78 million of cash, $1 billion of net operating loss carry forwards and various causes of action. NuRide intends to deploy its cash and intangible assets to (i) investigate and prosecute its causes of action, and (ii) identify, evaluate, and pursue one or more potential business combinations or acquisitions, as determined by the Board. NuRide has no debt apart from certain liabilities related to general unsecured claims filed in the bankruptcy case. Additional information about the company and the Plan of Reorganization is available on the company’s website (www.nurideinc.com) and in the company’s filings with the U.S. Securities and Exchange Commission available at www.sec.gov/edgar.
As of March 14, 2024, 15,953,212 shares of the registrant’s Class A common stock were outstanding.
78 million : 16 millon shares = $4.88/share
Nu Ride Inc (NRDE) : 2.3100+0.6000 (+35.09%)
On March 14, 2024, Nu Ride Inc. (NuRide), formerly known as Lordstown Motors Corp., emerged from bankruptcy as a public reporting company. The company emerged from bankruptcy with approximately $78 million of cash, $1 billion of net operating loss carry forwards and various causes of action. NuRide intends to deploy its cash and intangible assets to (i) investigate and prosecute its causes of action, and (ii) identify, evaluate, and pursue one or more potential business combinations or acquisitions, as determined by the Board. NuRide has no debt apart from certain liabilities related to general unsecured claims filed in the bankruptcy case. Additional information about the company and the Plan of Reorganization is available on the company’s website (www.nurideinc.com) and in the company’s filings with the U.S. Securities and Exchange Commission available at www.sec.gov/edgar.
As of March 14, 2024, 15,953,212 shares of the registrant’s Class A common stock were outstanding.
78 million : 16 millon shares = $4.88/share
Golden Heaven Group Holdings Ltd. Announces Guest Visits Increased During the 2024 Chinese Spring Festival Holiday
NANPING, China, March 6, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, today announces that it witnessed an increase in guest visits during the Chinese Spring Festival holiday ("Spring Festival holiday"), from February 10, 2024 to February 17, 2024. Golden Heaven's five amusement parks collectively had approximately 100,362 guest visits. This figure represents an approximately 28.4% increase in park attendance over the corresponding period in 2023, which recorded 78,189 guest visits from January 22, 2023 to January 29, 2023. This sets a new attendance record for Golden Heaven.
Guest visits of each park during Spring Festival holiday:
Tongling West Lake Amusement World: The number of guest visits was up 47.9% to 22,152, from 14,978 in the corresponding period last year.
Changde Jinsheng Amusement Park: The number of guest visits was up 33.1% to 20,256, from 15,218 in the corresponding period last year.
Yueyang Amusement World: The number of guest visits was slightly down 6.5% to 26,309, from 28,144 in the corresponding period last year.
Yunnan Yuxi Jinsheng Amusement Park: The number of guest visits was up 51.5% to 20,733 from 13,682 in the corresponding period last year.
Qujing Jinsheng Amusement Park: The number of guest visits was up 76.9% to 10,912, from 6,167 in the corresponding period last year.
A designated officer from the Company, commented, "We are thrilled that our amusement parks welcomed more guests in the Spring Festival holiday, marking a prosperous start to the year of 2024. Moving forward, we plan to continue to devise and carry out strategies to satisfy our guests' evolving needs and interests, which we anticipate will enable stronger revenue growth."
Golden Heaven Group Holdings Ltd. Announces Guest Visits Increased During the 2024 Chinese Spring Festival Holiday
NANPING, China, March 6, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, today announces that it witnessed an increase in guest visits during the Chinese Spring Festival holiday ("Spring Festival holiday"), from February 10, 2024 to February 17, 2024. Golden Heaven's five amusement parks collectively had approximately 100,362 guest visits. This figure represents an approximately 28.4% increase in park attendance over the corresponding period in 2023, which recorded 78,189 guest visits from January 22, 2023 to January 29, 2023. This sets a new attendance record for Golden Heaven.
Guest visits of each park during Spring Festival holiday:
Tongling West Lake Amusement World: The number of guest visits was up 47.9% to 22,152, from 14,978 in the corresponding period last year.
Changde Jinsheng Amusement Park: The number of guest visits was up 33.1% to 20,256, from 15,218 in the corresponding period last year.
Yueyang Amusement World: The number of guest visits was slightly down 6.5% to 26,309, from 28,144 in the corresponding period last year.
Yunnan Yuxi Jinsheng Amusement Park: The number of guest visits was up 51.5% to 20,733 from 13,682 in the corresponding period last year.
Qujing Jinsheng Amusement Park: The number of guest visits was up 76.9% to 10,912, from 6,167 in the corresponding period last year.
A designated officer from the Company, commented, "We are thrilled that our amusement parks welcomed more guests in the Spring Festival holiday, marking a prosperous start to the year of 2024. Moving forward, we plan to continue to devise and carry out strategies to satisfy our guests' evolving needs and interests, which we anticipate will enable stronger revenue growth."
ReShape Lifesciences Inc. (RSLS)
At close: 0.1739+0.0056 (+3.33%)
Pre-Market: 0.1999 +0.026 (+14.95%)
2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023
Company Reaffirms Commitment to Profitability
High Priority Search for Synergistic M&A Partner Continues
Company has no debt
IRVINE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced a 2024 cost reduction plan and reorganization to prioritize the commercialization of the company’s next generation, enhanced Lap-Band® 2.0 FLEX. Full implementation of the plan is expected to result in lower operating expenses of approximately $7.9 million in 2024 compared to $17.7 million in 2023, a 55.4% reduction, excluding one-time costs.
“ReShape remains committed to delivering shareholder value and, ultimately, profitability. Our continued focus on restructuring is intended to ensure the long-term sustainability and scalability of the Company,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “As we considered the impact of GLP-1 prescriptions for weight loss treatment, which has put pressure on the bariatric industry, it was necessary to take a hard look at our operations and make significant cost reductions including a further reduction in staff, leading to a projected 55.4% decrease in operating expenses for 2024, compared to last year. This reorganization and decrease in expenses will allow us to focus on and optimize the commercialization of our physician-led redesigned Lap-Band® 2.0 FLEX, designed to improve the patient experience, which is currently in the early launch stage.
“At the same time, we continue our high priority search for synergistic M&A opportunities and, as previously reported, have engaged Maxim Group LLC, on an exclusive basis, to assist in this process. Finding the right partner will be key to the long-term success of ReShape Lifesciences. We look forward to providing further updates during our year end 2024 earnings call, later this month,” concluded Mr. Hickey.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
ReShape Lifesciences Inc. (RSLS)
At close: 0.1739+0.0056 (+3.33%)
Pre-Market: 0.1999 +0.026 (+14.95%)
2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023
Company Reaffirms Commitment to Profitability
High Priority Search for Synergistic M&A Partner Continues
Company has no debt
IRVINE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced a 2024 cost reduction plan and reorganization to prioritize the commercialization of the company’s next generation, enhanced Lap-Band® 2.0 FLEX. Full implementation of the plan is expected to result in lower operating expenses of approximately $7.9 million in 2024 compared to $17.7 million in 2023, a 55.4% reduction, excluding one-time costs.
“ReShape remains committed to delivering shareholder value and, ultimately, profitability. Our continued focus on restructuring is intended to ensure the long-term sustainability and scalability of the Company,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “As we considered the impact of GLP-1 prescriptions for weight loss treatment, which has put pressure on the bariatric industry, it was necessary to take a hard look at our operations and make significant cost reductions including a further reduction in staff, leading to a projected 55.4% decrease in operating expenses for 2024, compared to last year. This reorganization and decrease in expenses will allow us to focus on and optimize the commercialization of our physician-led redesigned Lap-Band® 2.0 FLEX, designed to improve the patient experience, which is currently in the early launch stage.
“At the same time, we continue our high priority search for synergistic M&A opportunities and, as previously reported, have engaged Maxim Group LLC, on an exclusive basis, to assist in this process. Finding the right partner will be key to the long-term success of ReShape Lifesciences. We look forward to providing further updates during our year end 2024 earnings call, later this month,” concluded Mr. Hickey.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
GDHG : Great news
NANPING, China, Feb. 29, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, announced today that on February 26, 2024, it entered into a Letter of Intent for Strategic Partnership ("LOI") with PT BESTAR JAYA ("BESTAR"), an Indonesian trading company that services large-scale supermarkets nationwide, to launch a total of 30 to 50 indoor amusement parks in Indonesia.
According to the terms of the LOI, BESTAR is expected to open indoor amusement parks in major shopping centers and supermarkets in prime locations across Indonesia, and Golden Heaven will offer planning, layout design, facility procurement, operational management, staff training and other related services to BESTAR. Further details of this partnership will be disclosed as the ongoing negotiation progresses.
Ms. Qiong Jin, the CEO and Chairman of the Company, commented, "We are honored to be a part of this major project with BESTAR. This partnership highlights our entry into the international market and our dedication to delivering pleasant entertainment experiences to our customers. We are committed to our global expansion strategy to enhance our competitiveness through strategic partnerships and business innovation. We are looking forward to carrying forward this partnership and bringing our entertainment resources to the Indonesian market."
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
GDHG : Great news
NANPING, China, Feb. 29, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, announced today that on February 26, 2024, it entered into a Letter of Intent for Strategic Partnership ("LOI") with PT BESTAR JAYA ("BESTAR"), an Indonesian trading company that services large-scale supermarkets nationwide, to launch a total of 30 to 50 indoor amusement parks in Indonesia.
According to the terms of the LOI, BESTAR is expected to open indoor amusement parks in major shopping centers and supermarkets in prime locations across Indonesia, and Golden Heaven will offer planning, layout design, facility procurement, operational management, staff training and other related services to BESTAR. Further details of this partnership will be disclosed as the ongoing negotiation progresses.
Ms. Qiong Jin, the CEO and Chairman of the Company, commented, "We are honored to be a part of this major project with BESTAR. This partnership highlights our entry into the international market and our dedication to delivering pleasant entertainment experiences to our customers. We are committed to our global expansion strategy to enhance our competitiveness through strategic partnerships and business innovation. We are looking forward to carrying forward this partnership and bringing our entertainment resources to the Indonesian market."
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
GDHG: 0.54
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173902061
+ on February 21, 2024, the Company's Board of Directors (the "Board") has authorized a share repurchase program authorizing the Company to repurchase up to US$6,000,000 of the Company's outstanding Class A ordinary shares from time to time during a 24-month period
time for a strong rebound:
Feb 23, 2024 0.4700 0.4910 0.4100 0.4730 0.4730 6,324,343
Feb 19, 2024 0.4900 0.5670 0.4100 0.4730 0.4730 18,373,200
Feb 12, 2024 0.5700 0.6100 0.4500 0.5040 0.5040 19,012,600
Feb 05, 2024 0.6100 0.7690 0.4850 0.5700 0.5700 6,939,200
Jan 29, 2024 0.5750 0.8470 0.5400 0.6060 0.6060 5,034,100
Jan 22, 2024 0.4600 0.5600 0.4410 0.5440 0.5440 1,475,100
Jan 15, 2024 0.5510 0.5600 0.4400 0.4510 0.4510 1,080,700
Jan 08, 2024 0.6060 0.6200 0.5390 0.5600 0.5600 2,384,400
Jan 01, 2024 0.7450 0.7450 0.6130 0.6240 0.6240 2,211,100
Dec 25, 2023 1.0900 1.1200 0.7020 0.7300 0.7300 6,992,700
Dec 18, 2023 1.2400 1.4900 1.0700 1.1400 1.1400 6,038,400
Dec 11, 2023 1.1700 1.5500 1.0500 1.2900 1.2900 9,870,200
Dec 04, 2023 19.5300 22.3000 1.3300 1.3600 1.3600 17,464,600
Nov 27, 2023 22.5200 24.8300 19.7500 20.5500 20.5500 1,834,400
Nov 20, 2023 21.8200 24.3000 19.7500 23.4900 23.4900 1,428,500
Nov 13, 2023 23.0000 24.9900 11.0050 20.3900 20.3900 2,547,300
GDHG: 0.54
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173902061
+ on February 21, 2024, the Company's Board of Directors (the "Board") has authorized a share repurchase program authorizing the Company to repurchase up to US$6,000,000 of the Company's outstanding Class A ordinary shares from time to time during a 24-month period
time for a strong rebound:
Feb 23, 2024 0.4700 0.4910 0.4100 0.4730 0.4730 6,324,343
Feb 19, 2024 0.4900 0.5670 0.4100 0.4730 0.4730 18,373,200
Feb 12, 2024 0.5700 0.6100 0.4500 0.5040 0.5040 19,012,600
Feb 05, 2024 0.6100 0.7690 0.4850 0.5700 0.5700 6,939,200
Jan 29, 2024 0.5750 0.8470 0.5400 0.6060 0.6060 5,034,100
Jan 22, 2024 0.4600 0.5600 0.4410 0.5440 0.5440 1,475,100
Jan 15, 2024 0.5510 0.5600 0.4400 0.4510 0.4510 1,080,700
Jan 08, 2024 0.6060 0.6200 0.5390 0.5600 0.5600 2,384,400
Jan 01, 2024 0.7450 0.7450 0.6130 0.6240 0.6240 2,211,100
Dec 25, 2023 1.0900 1.1200 0.7020 0.7300 0.7300 6,992,700
Dec 18, 2023 1.2400 1.4900 1.0700 1.1400 1.1400 6,038,400
Dec 11, 2023 1.1700 1.5500 1.0500 1.2900 1.2900 9,870,200
Dec 04, 2023 19.5300 22.3000 1.3300 1.3600 1.3600 17,464,600
Nov 27, 2023 22.5200 24.8300 19.7500 20.5500 20.5500 1,834,400
Nov 20, 2023 21.8200 24.3000 19.7500 23.4900 23.4900 1,428,500
Nov 13, 2023 23.0000 24.9900 11.0050 20.3900 20.3900 2,547,300
Jaguar Health Inc (jagx) : premarket: 0.07 + 0.01 (16.64%)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173919208
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173917616
I’m hoping for at least 0.1 (this week)
Jaguar health stock price in Germany: 0.0735 euro (x1.0844) = $0.0797
Jaguar Health Inc (jagx) : premarket: 0.07 + 0.01 (16.64%)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173919208
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173917616
I’m hoping for at least 0.1 (this week)
Jaguar health stock price in Germany: 0.0735 euro (x1.0844) = $0.0797
A month ago:
Jan 26, 2024 0.1410 0.1480 0.1110 0.1130 0.1130 104,343,500
Jan 25, 2024 0.1030 0.1190 0.0980 0.1150 0.1150 28,943,40
It's time shorters start to cover!!!
Settlement Date Short Interest Avg. Daily Share Volume Days to Cover
01/31/2024 4,111,288
01/12/2024 2,947,821
12/29/2023 708,904
Jagx: 0.06
52 Week Range 0.0510 - 2.3000
https://jaguar.health/pipeline/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173911094
Product revenue more than 10 million for 2023
Total assets $ 45,380,000
millions shares are short.
Free float of less than $2,500,000
Iliad Research & Trading LP : 4,875,000
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9.6 %
Based on the 50,755,580 shares outstanding
Time for a very strong rebound:
Feb 23, 2024 0.0570 0.0619 0.0525 0.0600 0.0600 24,872,714
Feb 19, 2024 0.0720 0.0730 0.0510 0.0600 0.0600 82,160,200
Feb 12, 2024 0.0890 0.0960 0.0770 0.0780 0.0780 78,923,400
Feb 05, 2024 0.0960 0.0960 0.0770 0.0840 0.0840 62,062,300
Jan 29, 2024 0.1090 0.1160 0.0930 0.0970 0.0970 92,774,500
Jan 22, 2024 0.1020 0.1480 0.0950 0.1130 0.1130 163,317,200
Jan 15, 2024 0.0980 0.1070 0.0860 0.1010 0.1010 42,693,800
Jan 08, 2024 0.1400 0.1400 0.1020 0.1030 0.1030 74,868,000
Jan 01, 2024 0.1520 0.1560 0.1310 0.1400 0.1400 15,049,600
Dec 25, 2023 0.1700 0.1750 0.1500 0.1510 0.1510 14,160,900
Dec 18, 2023 0.1650 0.1680 0.1460 0.1670 0.1670 19,167,400
Dec 11, 2023 0.2250 0.2290 0.1510 0.1600 0.1600 38,737,500
Dec 04, 2023 0.3500 0.4050 0.2650 0.2650 0.2650 28,157,100
Nov 27, 2023 0.3600 0.3830 0.2910 0.3560 0.3560 15,147,500
Nov 20, 2023 0.4250 0.5140 0.3300 0.3740 0.3740 30,015,800
Nov 13, 2023 0.2980 0.4210 0.2850 0.4070 0.4070 20,367,600
Nov 06, 2023 0.3000 0.3370 0.2580 0.2920 0.2920 19,674,600
Oct 29, 2023 0.3310 0.3640 0.3170 0.3200 0.3200 13,055,100
Oct 22, 2023 0.3220 0.4000 0.3000 0.3250 0.3250 16,088,700
Oct 15, 2023 0.3200 0.3750 0.2100 0.3300 0.3300 45,452,000
Oct 08, 2023 0.2520 0.5290 0.2250 0.3200 0.3200 142,429,30
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
Jagx: 0.06
52 Week Range 0.0510 - 2.3000
https://jaguar.health/pipeline/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173911094
Product revenue more than 10 million for 2023
Total assets $ 45,380,000
millions shares are short.
Free float of less than $2,500,000
Iliad Research & Trading LP : 4,875,000
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9.6 %
Based on the 50,755,580 shares outstanding
Time for a very strong rebound:
Feb 23, 2024 0.0570 0.0619 0.0525 0.0600 0.0600 24,872,714
Feb 19, 2024 0.0720 0.0730 0.0510 0.0600 0.0600 82,160,200
Feb 12, 2024 0.0890 0.0960 0.0770 0.0780 0.0780 78,923,400
Feb 05, 2024 0.0960 0.0960 0.0770 0.0840 0.0840 62,062,300
Jan 29, 2024 0.1090 0.1160 0.0930 0.0970 0.0970 92,774,500
Jan 22, 2024 0.1020 0.1480 0.0950 0.1130 0.1130 163,317,200
Jan 15, 2024 0.0980 0.1070 0.0860 0.1010 0.1010 42,693,800
Jan 08, 2024 0.1400 0.1400 0.1020 0.1030 0.1030 74,868,000
Jan 01, 2024 0.1520 0.1560 0.1310 0.1400 0.1400 15,049,600
Dec 25, 2023 0.1700 0.1750 0.1500 0.1510 0.1510 14,160,900
Dec 18, 2023 0.1650 0.1680 0.1460 0.1670 0.1670 19,167,400
Dec 11, 2023 0.2250 0.2290 0.1510 0.1600 0.1600 38,737,500
Dec 04, 2023 0.3500 0.4050 0.2650 0.2650 0.2650 28,157,100
Nov 27, 2023 0.3600 0.3830 0.2910 0.3560 0.3560 15,147,500
Nov 20, 2023 0.4250 0.5140 0.3300 0.3740 0.3740 30,015,800
Nov 13, 2023 0.2980 0.4210 0.2850 0.4070 0.4070 20,367,600
Nov 06, 2023 0.3000 0.3370 0.2580 0.2920 0.2920 19,674,600
Oct 29, 2023 0.3310 0.3640 0.3170 0.3200 0.3200 13,055,100
Oct 22, 2023 0.3220 0.4000 0.3000 0.3250 0.3250 16,088,700
Oct 15, 2023 0.3200 0.3750 0.2100 0.3300 0.3300 45,452,000
Oct 08, 2023 0.2520 0.5290 0.2250 0.3200 0.3200 142,429,30
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
GDHG: 0.48
They can buy the free float 🤑
Shares Outstanding 41.75M
Float 11.74M
NANPING, China, Feb. 22, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, announced today that on February 21, 2024, the Company's Board of Directors (the "Board") has authorized a share repurchase program authorizing the Company to repurchase up to US$6,000,000 of the Company's outstanding Class A ordinary shares from time to time during a 24-month period (the "Share Repurchase Program"). The Share Repurchase Program will be facilitated by Dawson James Securities, Inc.
The Board has determined that the Share Repurchase Program is in the best interest of the Company's shareholders based on its analysis and estimation that the current share price is significantly lower than the intrinsic value and that the Share Repurchase Program may improve shareholders' confidence in the Company. The Board will be periodically reviewing the Share Repurchase Program and may authorize adjustments of its terms and size.
In determining the amount of capital to allocate to share repurchases, the Company takes into account, among other things, its historical and expected business performance, cash and liquidity position, as well as global economic and market conditions and the market price of the Company's Class A ordinary shares. The timing, manner, price, and amount of any repurchases under the Share Repurchase Program are determined by the Company in its discretion. Purchases may be affected through open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or other means. The Company is not obligated to repurchase any specific number of Class A ordinary shares and the program may be modified, suspended, or discontinued at any time.
The Company intends to make all repurchases in compliance with applicable regulatory guidelines and to administer the plan in accordance with applicable laws.
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
GDHG: 0.48
They can buy the free float 🤑
Shares Outstanding 41.75M
Float 11.74M
NANPING, China, Feb. 22, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, announced today that on February 21, 2024, the Company's Board of Directors (the "Board") has authorized a share repurchase program authorizing the Company to repurchase up to US$6,000,000 of the Company's outstanding Class A ordinary shares from time to time during a 24-month period (the "Share Repurchase Program"). The Share Repurchase Program will be facilitated by Dawson James Securities, Inc.
The Board has determined that the Share Repurchase Program is in the best interest of the Company's shareholders based on its analysis and estimation that the current share price is significantly lower than the intrinsic value and that the Share Repurchase Program may improve shareholders' confidence in the Company. The Board will be periodically reviewing the Share Repurchase Program and may authorize adjustments of its terms and size.
In determining the amount of capital to allocate to share repurchases, the Company takes into account, among other things, its historical and expected business performance, cash and liquidity position, as well as global economic and market conditions and the market price of the Company's Class A ordinary shares. The timing, manner, price, and amount of any repurchases under the Share Repurchase Program are determined by the Company in its discretion. Purchases may be affected through open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or other means. The Company is not obligated to repurchase any specific number of Class A ordinary shares and the program may be modified, suspended, or discontinued at any time.
The Company intends to make all repurchases in compliance with applicable regulatory guidelines and to administer the plan in accordance with applicable laws.
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
Wish: 6.95
52w high 25.17
Time we see at least $8.
ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) announced that its Board of Directors (the “Board”) has unanimously approved an agreement to sell substantially all of its operating assets and liabilities, principally comprising its Wish ecommerce platform, to Qoo10, an ecommerce platform operating localized online marketplaces in Asia, for approximately $173 million in cash, subject to certain purchase price adjustments.
Following closing of the transaction, ContextLogic will have limited operating expenses and a balance sheet that will be debt-free, with net cash proceeds from the asset sale, approximately $2.7 billion of Net Operating Loss (“NOL”) carryforwards and certain retained assets. The Board intends to use the proceeds from the transaction to help monetize its NOLs. The Board also intends to explore the opportunity for a financial sponsor to help ContextLogic realize the value of its tax assets.
$173 million + 5% of $2.7 billion = $308 million : 24.230.000 shares = $12.72/share
Wish: 6.95
52w high 25.17
Time we see at least $8.
ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) announced that its Board of Directors (the “Board”) has unanimously approved an agreement to sell substantially all of its operating assets and liabilities, principally comprising its Wish ecommerce platform, to Qoo10, an ecommerce platform operating localized online marketplaces in Asia, for approximately $173 million in cash, subject to certain purchase price adjustments.
Following closing of the transaction, ContextLogic will have limited operating expenses and a balance sheet that will be debt-free, with net cash proceeds from the asset sale, approximately $2.7 billion of Net Operating Loss (“NOL”) carryforwards and certain retained assets. The Board intends to use the proceeds from the transaction to help monetize its NOLs. The Board also intends to explore the opportunity for a financial sponsor to help ContextLogic realize the value of its tax assets.
$173 million + 5% of $2.7 billion = $308 million : 24.230.000 shares = $12.72/share
Wish: Time we see at least $8.
ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) announced that its Board of Directors (the “Board”) has unanimously approved an agreement to sell substantially all of its operating assets and liabilities, principally comprising its Wish ecommerce platform, to Qoo10, an ecommerce platform operating localized online marketplaces in Asia, for approximately $173 million in cash, subject to certain purchase price adjustments.
Following closing of the transaction, ContextLogic will have limited operating expenses and a balance sheet that will be debt-free, with net cash proceeds from the asset sale, approximately $2.7 billion of Net Operating Loss (“NOL”) carryforwards and certain retained assets. The Board intends to use the proceeds from the transaction to help monetize its NOLs. The Board also intends to explore the opportunity for a financial sponsor to help ContextLogic realize the value of its tax assets.
$173 million + 5% of $2.7 billion = $308 million : 24.230.000 shares = $12.72/share
Wish: Time we see at least $8.
ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) announced that its Board of Directors (the “Board”) has unanimously approved an agreement to sell substantially all of its operating assets and liabilities, principally comprising its Wish ecommerce platform, to Qoo10, an ecommerce platform operating localized online marketplaces in Asia, for approximately $173 million in cash, subject to certain purchase price adjustments.
Following closing of the transaction, ContextLogic will have limited operating expenses and a balance sheet that will be debt-free, with net cash proceeds from the asset sale, approximately $2.7 billion of Net Operating Loss (“NOL”) carryforwards and certain retained assets. The Board intends to use the proceeds from the transaction to help monetize its NOLs. The Board also intends to explore the opportunity for a financial sponsor to help ContextLogic realize the value of its tax assets.
$173 million + 5% of $2.7 billion = $308 million : 24.230.000 shares = $12.72/share